United Therapeutics is trading 4.03% down at $469.68 after Goldman Sachs initiated coverage on September 24, 2026, with a Sell rating and a $321 price target, citing a negatively skewed risk-reward setup.
- Higher Treasury yields and a weaker biotechnology sector are adding downside momentum.
- The analyst action appears to be the clearest company-specific catalyst.